Combining AI and computational chemistry, we developed a series of innovative methods to address challenging drug discovery and design tasks, including molecular structure generation, binding affinity prediction, and key drug property predictions. Based on these AI-empowered capabilities, we are working with industry partners in the one-stop drug discovery of small molecules and macromolecule services, to improve research efficiency, reduce costs, and increase the overall success rate of innovative therapeutics in R&D.
SHENZHEN, China and BOSTON-XtalPi, a physics-based, AI-powered pharmatech, announced a partnership with MIT Professor of Chemistry Bradley L. Pentelute to advance research in peptide chemistry and molecular biology.
Expanding the tried-and-true "AI drug discovery + novel organoid disease models" paradigm to new cancer drug pipeline collaboration
Named as one of the most promising private med-tech companies in the industry